-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Hidradenitis Suppurativa Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Lupus Nephritis Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Polyarticular Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Polyarticular Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Polyarticular Arthritis Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Psoriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Psoriasis Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is a human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Pulmonary Sarcoidosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Pulmonary Sarcoidosis Drug Details: efzofitimod (ATYR-1923) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – L-608 in Pulmonary Arterial Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. L-608 in Pulmonary Arterial Hypertension Drug Details: L-608 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-7240 in Ulcerative Colitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MK-7240 in Ulcerative Colitis Drug Details: MK-7240 is under development for the treatment of inflammatory...